{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:39:32Z","timestamp":1780609172979,"version":"3.54.1"},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Fundaci\u00f3n Instituto Te\u00f3filo Hernando"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Inflammation and overexpression of cyclooxygenase\u20102 (COX\u20102) have been described to play a key role in the progression from nonpathologic intestinal mucosa to colorectal cancer (CRC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To assess the chemoprotective effect of non\u2010aspirin nonsteroidal anti\u2010inflammatory drugs (NA\u2010NSAIDs) under different patterns of use in a Mediterranean population and to explore the potential effect of symptomatic slow\u2010acting drugs for osteoarthritis (SYSADOAs; chondroitin sulfate and glucosamine) and metamizole (or dipyrone), also reported to influence COX\u20102 activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a case\u2010control study nested in a cohort extracted from the primary care database, BIFAP. From 2001 to 2014, we included 15\u00a0491 incident cases and 60\u00a0000 random controls. To estimate the association between the drugs of interest and CRC, we built logistic regression models to compute the adjusted\u2010odds ratios (AOR) and 95% confidence intervals (CI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>NA\u2010NSAIDs use was associated with a reduced risk of CRC (AOR\u00a0=\u00a00.67; 95% CI: 0.63\u20100.71) and increased linearly with duration of treatment (<jats:italic>p<\/jats:italic> for trend &lt;0.001). The effect diminished upon discontinuation but persisted statistically significant up to 1\u00a0year. All individual NA\u2010NSAIDs examined showed a decreased risk. The concomitant use of proton\u2010pump inhibitors (PPI) had no impact on the protective effect of NA\u2010NSAIDs; AOR<jats:sub>PPI\u00a0+\u00a0NSAID<\/jats:sub>\u00a0=\u00a00.64; 0.58\u20100.71. SYSADOA use was associated with a reduced risk (0.79; 0.69\u20100.90) but disappeared after the exclusion of NSAID users during the previous 1 or 3\u00a0years (0.85; 0.70\u20101.04 and 1.00; 0.76\u20101.31 respectively). Metamizole did not show a chemoprotective effect.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>NA\u2010NSAID use is associated with a duration\u2010dependent risk reduction of CRC not shared by SYSADOAs or metamizole.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.15333","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T07:53:12Z","timestamp":1563349992000},"page":"295-305","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Population\u2010based case\u2010control study: chemoprotection of colorectal cancer with non\u2010aspirin nonsteroidal anti\u2010inflammatory drugs and other drugs for pain control"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0799-1612","authenticated-orcid":false,"given":"Antonio","family":"Rodr\u00edguez\u2010Miguel","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Unit University Hospital \u201cPr\u00edncipe de Asturias\u201d Madrid Spain"},{"name":"Department of Biomedical Sciences, Pharmacology Unit, School of Medicine University of Alcal\u00e1 (IRYCIS) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-2709","authenticated-orcid":false,"given":"Luis A.","family":"Garc\u00eda\u2010Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Spanish Centre for Pharmacoepidemiologic Research (CEIFE) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Gil","sequence":"additional","affiliation":[{"name":"BIFAP Unit, Pharmacoepidemiology and Pharmacovigilance Division Spanish Agency for Medicines and Clinical Devices (AEMPS) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7200-3345","authenticated-orcid":false,"given":"Diana","family":"Barreira\u2010Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit University Hospital \u201cPr\u00edncipe de Asturias\u201d Madrid Spain"},{"name":"Department of Biomedical Sciences, Pharmacology Unit, School of Medicine University of Alcal\u00e1 (IRYCIS) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-1470","authenticated-orcid":false,"given":"Sara","family":"Rodr\u00edguez\u2010Mart\u00edn","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit University Hospital \u201cPr\u00edncipe de Asturias\u201d Madrid Spain"},{"name":"Department of Biomedical Sciences, Pharmacology Unit, School of Medicine University of Alcal\u00e1 (IRYCIS) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-8646","authenticated-orcid":false,"given":"Francisco J.","family":"de Abajo","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit University Hospital \u201cPr\u00edncipe de Asturias\u201d Madrid Spain"},{"name":"Department of Biomedical Sciences, Pharmacology Unit, School of Medicine University of Alcal\u00e1 (IRYCIS) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61649-9"},{"key":"e_1_2_7_3_1","volume-title":"La situaci\u00f3n del c\u00e1ncer en Espa\u00f1a: Informe 2015","author":"L\u00f3pez\u2010Abente G","year":"2015"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.421"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i22.6786"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945011798184218"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071014"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000366037"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0577"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805819"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804988"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31924-X"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-5-200703060-00010"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3757-8"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2018.11.002"},{"key":"e_1_2_7_16_1","first-page":"1612","article-title":"Upregulation of cyclooxygenase\u20102 is associated with activation of the alternative nuclear factor kappa B signaling pathway in colonic adenocarcinoma","volume":"7","author":"Shi G","year":"2015","journal-title":"Am J Transl Res"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2014.03.033"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20349-6"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30250"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-013-0192-2"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-018-1003-6"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-0038"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-8061com"},{"key":"e_1_2_7_24_1","unstructured":"BIFAP.Base de datos para la Investigaci\u00f3n Farmacoepidemiol\u00f3gica en Atenci\u00f3n Primaria.www.bifap.org. Accessed December 4 2018."},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574884708666131111211802"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/pds.4686","article-title":"Validation study of colorectal cancer diagnosis in the Spanish primary care database, BIFAP","volume":"2019","author":"Gil M","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_7_27_1","unstructured":"2008 Wolter Kluwer\/Lippincott William & Wilkins Philadelphia PA K Rothman S Greenland TS Lash K Rothman S Greenland TS Lash Case\u2010control studies 111 127"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.110977"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7382.219"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-30331-9_2"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2014.04.008"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S175212"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.03.004"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-582"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1573"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4274(99)00210-6"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i17.5382"},{"issue":"14","key":"e_1_2_7_38_1","first-page":"s273","article-title":"The role of dose reduction with NSAID use","volume":"19","author":"Matthews ML","year":"2013","journal-title":"Am J Manag Care"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.12.012"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4675"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206792"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210860"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0836-y"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427060-00005"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.15333","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.15333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T19:25:54Z","timestamp":1694287554000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.15333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,17]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/apt.15333"],"URL":"https:\/\/doi.org\/10.1111\/apt.15333","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,17]]},"assertion":[{"value":"2019-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}